ConductScience.org, home

Paper17513327

IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.

Coppo R and 7 others. J Am Soc Nephrol, 2007. Cited by 191 papers, by iCite.

Cite this record

ConductScience Library. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. Papers, record 17513327. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17513327

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
PubMed
Journal
J Am Soc Nephrol
PubMed
Year
2007
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
191
iCite
Relative citation ratio, by iCite
5.6
iCite
Revised in PubMed
2022-04-09
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Coppo RRosanna
2Peruzzi LLicia
3Amore AAlessandro
4Piccoli AAntonio
5Cochat PPierre
6Stone RRosario
7Kirschstein MMartin
8Linné TTommy

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiotensin-Converting Enzyme InhibitorsMajor topic
BenzazepinesMajor topic
Glomerulonephritis, IGAMajor topic
ProteinuriaMajor topic
Adolescent
Adult
Child
Disease Progression
Female
Follow-Up Studies
Humans
Male
Placebos
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Risk Factors
Severity of Illness Index
Treatment Outcome

Source PubMed

Download CSV of topics

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in17494880Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?https://conductscience.org/library/papers/17494880PubMed
Comment in17848928Is angiotensin-converting-enzyme inhibition renoprotective in young patients with IgA nephropathy?https://conductscience.org/library/papers/17848928PubMed

Download CSV of comments and corrections

Cited by109

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 191 citations.

PMIDTitleJournalYearIn PapersSource
42953388Treatment and practical considerations of IgA nephropathy.Front Med (Lausanne)2026https://conductscience.org/library/papers/42953388PubMed
42483537Management of IgA nephropathy and the expanding role of immunomodulation.Kidney Int Suppl (2011)2026https://conductscience.org/library/papers/42483537PubMed
42379652Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort.Lupus Sci Med2026https://conductscience.org/library/papers/42379652PubMed
41807808Global research trends and hotspots in targeted therapy for IgA nephropathy: a bibliometric and visualization analysis (1999-2025).Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41807808PubMed
41767692Open-label Randomized Controlled Trial of Controlled-release Formulation Budesonide in Indian Proteinuric IgA Nephropathy Patients.Kidney Med2026https://conductscience.org/library/papers/41767692PubMed
41746490Recent trends in dialysis initiation in Japan: a region‑specific descriptive analysis using Hokkaido as an example.Clin Exp Nephrol2026https://conductscience.org/library/papers/41746490PubMed
41704425Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.Clin Kidney J2026https://conductscience.org/library/papers/41704425PubMed
41502882Optimal drug treatment for children with IgA vasculitis nephritis: a systematic review and network meta-analysis.Transl Pediatr2025https://conductscience.org/library/papers/41502882PubMed
40869540Bradykinin-Mediated Angioedema Induced by Drugs.J Clin Med2025https://conductscience.org/library/papers/40869540PubMed
40606442Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.Front Med (Lausanne)2025https://conductscience.org/library/papers/40606442PubMed
40493692Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.PLoS One2025https://conductscience.org/library/papers/40493692PubMed
40328660Immune cells mediate the effect of plasma lipidomes on IgA nephropathy: a Mendelian randomization study.Ren Fail2025https://conductscience.org/library/papers/40328660PubMed
39928268Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies.Paediatr Drugs2025https://conductscience.org/library/papers/39928268PubMed
39331079IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatr Nephrol2025https://conductscience.org/library/papers/39331079PubMed
39248402Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study.Ren Fail2024https://conductscience.org/library/papers/39248402PubMed
39188719Contemporary review of IgA nephropathy.Front Immunol2024https://conductscience.org/library/papers/39188719PubMed
38799377External Validation of the International IgA Nephropathy Prediction Tool in Older Adult Patients.Clin Interv Aging2024https://conductscience.org/library/papers/38799377PubMed
38576821Immunoglobulin A glomerulonephropathy: A review.World J Clin Cases2024https://conductscience.org/library/papers/38576821PubMed
38299639Non-immunosuppressive treatment for IgA nephropathy.Cochrane Database Syst Rev2024https://conductscience.org/library/papers/38299639PubMed
37947938Could mesangial C3 deposition be an independent prognostic marker in immunoglobulin A nephropathy?J Nephrol2024https://conductscience.org/library/papers/37947938PubMed

See all 109 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17513327

GET https://conductscience.org/api/papers/v1/17513327/cited_by?page=2